Keyphrases
Type 2 Diabetes Mellitus (T2DM)
95%
Hemoglobin A1c (HbA1c)
45%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
40%
Third-line Therapy
36%
Glucose-lowering Drugs
33%
Dipeptidyl peptidase-4 (DPP-4)
26%
Drug Class
25%
Metformin
25%
Sulfonylurea
24%
Clinical Features
24%
Second-line Therapy
21%
Sitagliptin
19%
Canagliflozin
19%
Thiazolidinediones
18%
Clinical Practice Research Datalink
17%
Glycemic Response
16%
Pioglitazone
16%
Adjusted Hazard Ratio
16%
Optimal Therapy
14%
Targeted Treatment
14%
Model-driven Development
13%
GLP-1 Receptor Agonist
13%
Type 2 Diabetic Patients
12%
Diabetes Drugs
12%
Glucagon-like
11%
A1 Receptor
11%
Receptor Agonist
11%
Primary Care Data
11%
Metformin Use
10%
Low HbA1c
10%
Patient Stratification
10%
Suboptimal Glycemic Control
10%
Metformin Treatment
10%
Diabetes Therapy
10%
Risk Factors
10%
Inhibitor-1
10%
Patient Preference
10%
Time Trends
10%
Retrospective Analysis
10%
Randomized Double-blind Crossover Study
10%
Anemia
10%
Response Factor
10%
UK Population
10%
Instrumental Variable Method
10%
Development Validation
10%
Model Validation
10%
Validation Studies
10%
Prediction Model
10%
Vascular Complications
10%
Drug Use Initiation
9%
Hemoglobin
9%
Randomized Double-blind
9%
Glycemic Efficacy
8%
Scotland
8%
Precision Medicine
8%
Glycemic Outcomes
7%
Treatment Options
7%
Diabetes
6%
All-cause Mortality
6%
Low Risk
6%
Hypoglycemia
6%
Drug Model
6%
Clinical Characteristics
6%
Adverse Events
6%
Anaemia Risk
5%
Diabetes Outcomes
5%
Drug Response
5%
Clinical Trials
5%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
71%
Sodium Glucose Cotransporter 2 Inhibitor
38%
Hemoglobin A1c
36%
Glycon
29%
Glycemic
21%
Sulfonylurea
21%
Sitagliptin
19%
Canagliflozin
19%
Diabetes
18%
Cotransporter
16%
Pioglitazone
16%
Side Effect
16%
Glycemic Control
14%
Thiazolidinedione
14%
Primary Health Care
13%
Patient with Type 2 Diabetes
11%
Anemia
10%
Targeted Therapy
10%
Glucagon-Like Peptide-1 Agonist
10%
Patient Preference
10%
Instrumental Variable Analysis
10%
Dipeptidyl Peptidase-4 Inhibitor
10%
Hypoglycemia
8%
Body Mass Index
8%
Personalized Medicine
7%
Adverse Event
6%
Systolic Blood Pressure
5%
Glycated Hemoglobin
5%
Blood Pressure
5%
Drug Response
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Hemoglobin A1c
55%
Sodium Glucose Cotransporter 2 Inhibitor
40%
Metformin
29%
Sulfonylurea
24%
Clinical Feature
24%
Sitagliptin
19%
Canagliflozin
19%
Cotransporter
18%
Thiazolidinedione
18%
Side Effect
16%
Pioglitazone
16%
Glucagon Like Peptide 1 Receptor Agonist
12%
Dipeptidyl Peptidase IV Inhibitor
11%
Anemia
10%
Hypoglycemia
8%
Clinical Trial
8%
All Cause Mortality
7%
Glycosylated Hemoglobin
6%
Adverse Event
6%
Tolerability
5%